Xencor | XNCR - Sales Revenues


Xencor reported $51.22M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.1B 1.48B Jun/2026
Arrowhead Research USD 75.23M 1.49M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 18.1B 1.5B Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 15.03B 530M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Xencor USD 51.22M 46.71M Jun/2026